BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)
- Registration Number
- NCT00887601
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
This study will evaluate functional magnetic resonance imaging (fMRI) and methods for measuring drug induced changes in cerebral blood flow as biomarkers for attention-improving drugs.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 32
Inclusion Criteria
- Subject is a nonsmoker
- Subject is in generally good health
- Subject has normal (or corrected to normal) vision and hearing
- Subject is right-handed
Exclusion Criteria
- Subject has a history of any illness that would make participation unsafe or would make the study results difficult to interpret
- Subject has a history of stroke, seizures, or major neurological disorders
- Subject has a history of cancer
- Subject has permanent cosmetic or metallic implants that would interfere with measurements
- Subject has a history of sleep apnea
- Subject has a history of head injury/trauma
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Part I Donepezil Subjects will receive placebo, MK3134, and donepezil in one of four treatment sequences. Part I MK3134 Subjects will receive placebo, MK3134, and donepezil in one of four treatment sequences. Part II MK3134 Subjects will receive placebo and three different doses of MK3134 (1 mg, 5 mg, and 25 mg) in one of four treatment sequences.
- Primary Outcome Measures
Name Time Method Part I: Difference in number of voxels activated for both faces and scenes after treatment with donepezil and placebo 3.5 to 4.5 hours after study drug administration Part II: Number of voxels showing a positive response after varying doses of MK3134 compared to placebo 3.5 to 4.5 hours after study drug administration Part I: Difference in number of voxels showing a positive response after treatment with donepezil and placebo 3.5 to 4.5 hours after study drug administration Part II: Number of voxels activated for both faces and scenes after varying doses of MK3134 compared to placebo 3.5 to 4.5 hours after study drug administration
- Secondary Outcome Measures
Name Time Method Part I: Test-retest reproducibility of the BOLD fMRI and cerebral blood flow measurements in donepezil treated subjects 1 to 5 weeks Part II: Change in arterial transit time after treatment with placebo and varying doses of MK3134 3.5 to 4.5 hours after study drug administration Part II: Change in Pulsatility index after treatment with placebo and varying doses of MK3134 5 hours after study drug administration Part I: Difference in Pulsatility index after treatment with donepezil and placebo 5 hours after study drug administration Part I: Difference in arterial transit time as measured by arterial spin labeling after treatment with donepezil and placebo 3.5 to 4.5 hours after study drug administration
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the cognitive effects of donepezil and MK3134 in dementia patients?
How does BOLD fMRI correlate with cerebral blood flow changes as biomarkers for cognition-enhancing drugs in NCT00887601?
What is the comparative effectiveness of donepezil versus MK3134 in early-stage dementia trials?
Which biomarkers predict response to cholinesterase inhibitors like donepezil in Alzheimer's disease subtypes?
What adverse events are associated with acetylcholinesterase inhibitors in phase 1 dementia studies?